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OBJECTIVES We studied the association of diabetes transmission with left ventricular hypertrophy (LVH)
in patients with non–insulin-dependent diabetes mellitus (NIDDM).
BACKGROUND It is suggested that NIDDM has a strong genetic basis and that maternally transmitted
NIDDM is associated with mitochondrial deoxyribonucleic acid (DNA) mutations. How-
ever, genetic factors for LVH in NIDDM are unknown.
METHODS We investigated the family history of diabetes and the prevalence of LVH using electrocar-
diography in 834 patients with NIDDM, of whom 199 also underwent echocardiography.
RESULTS Of the 834 patients, 121 had diabetic mothers, 122 had diabetic fathers and 30 had both. The
LVH criterion of SV1 1 RV5 or RV6 .35 mm was met in 148 patients. The percentage of
patients having diabetic mothers was higher in those with LVH criterion (29%) than without
it (16%) (p , 0.001), but the percentage of patients having diabetic fathers was similar in
those with LVH (18%) and without it (18%). Compared with the 683 patients with
nondiabetic mothers, the 151 patients with diabetic mothers were younger and had earlier
onset of diabetes. The percentage of patients having diabetic siblings was also higher in those
with diabetic mothers (31%) than in those with nondiabetic mothers (18%) (p , 0.001). On
electrocardiograms, the prevalence of LVH was higher in patients with diabetic mothers
(28%) than in those with nondiabetic mothers (15%) (p , 0.001). Echocardiograms showed
that patients with diabetic mothers had greater left ventricular wall thickness and mass than
those with nondiabetic mothers. In multivariate analysis, the family history of diabetes in
mothers was an independent factor to LVH, but the family history of diabetes in fathers was
not.
CONCLUSIONS Maternal transmission of diabetes was associated with LVH in patients with NIDDM. Some
genetic factors of diabetes, such as mitochondrial DNA abnormalities, may contribute to the
development of LVH in maternally transmitted NIDDM. (J Am Coll Cardiol 1999;33:
1372–8) © 1999 by the American College of Cardiology
Several clinical studies have demonstrated that diabetic
patients have greater left ventricular (LV) mass and LV wall
thickness than healthy subjects (1–4). The Framingham
Heart Study reported that hypertension and obesity often
coexist in diabetic patients (5). Because hypertension and
obesity are strong contributing factors to LV hypertrophy
(LVH) (6–8), LVH in diabetes could be attributed to those
concomitant factors. However, Lonn et al. (9) and Lee et al.
(10) recently documented that diabetes mellitus is associated
with LVH independent of hypertension and obesity.
Non–insulin-dependent diabetes mellitus (NIDDM) is a
disease strongly associated with genetic factors. A strong
genetic basis in NIDDM has been suggested by the high
concordance in monozygotic twins and the high incidence
of diabetes among the first-degree relatives of NIDDM
patients (11–13). We hypothesized that LVH in NIDDM
may be related to the genetic factors of diabetes. To know
the effect of diabetes transmission on LVH in NIDDM, we
investigated the family history of diabetes and the preva-
lence of LVH using 12-lead electrocardiography in patients
with NIDDM.
METHODS
Study subjects. We examined 834 consecutive patients
with NIDDM (mean age 58 6 9 years, range 40 to 79 years)
who were admitted to a two-week educational program for
diabetic patients at Tokyo Saiseikai Central Hospital from
January 1995 to December 1996. The diagnosis of NIDDM
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had been made by diabetologists according to the World
Health Organization criteria. On the first day of the
admission, blood samples were taken. On the second day, all
patients had 12-lead electrocardiography and the measure-
ments of blood pressures at rest. They were investigated by
the questionnaire as to whether their parents or siblings had
diabetes. Patients with secondary diabetes or bundle branch
blocks were excluded from this study.
Electrocardiography. Standard 12-lead electrocardio-
grams (ECGs) were recorded at rest in a supine position at
25 mm/s and 1 mV/cm using a Mac PC electrocardiograph
(Marquette, Milwaukee, Wisconsin) and were interpreted
blindly to all clinical data. For each lead, R-wave and
S-wave voltages were measured from the PR segment to the
top of the R wave and the bottom of the S wave, respec-
tively. The precordial voltage combination of Sokolow and
Lyon (14) was measured as SV1 1 higher RV5 or RV6. We
considered the ECG to inscribe LVH if SV1 1 RV5 or RV6
was .35 mm. In addition, the Romhilt–Estes point score
for LVH was calculated, based on the presence or absence of
QRS amplitude criteria (3 points), ST-T abnormalities
typical of LVH (3 points with no digitalis or 1 with
digitalis), left atrial abnormality (3 points), left axis devia-
tion $230 (2 points) and QRS duration $0.09 s or
intrinsicoid deflection $0.05 s (1 point each) (15). Q waves
were considered to be abnormal if their duration was
$0.04 s or if their depth was $1/4 of the height of the
ensuing R wave.
Echocardiography. Of the 834 study patients, 199 also
underwent echocardiography because of suspected or proven
coronary artery disease (93 patients), the long duration or
poor control of diabetes (81 patients), arrhythmias (14
patients) and suspected LVH (13 patients). M-mode and
two-dimensional echocardiography were performed using a
Sonos 1500 or 2500 ultrasonograph (Hewlett-Packard,
Andover, Massachusetts). On M-mode echocardiograms,
interventricular septum (IVS), posterior wall thickness
(PWT) and LV end-diastolic (LVIDd) and end-systolic
(LVIDs) internal dimensions were measured blindly to all
clinical data, according to the recommendations of the
American Society of Echocardiography. Fractional shorten-
ing and LV mass were calculated as follows: fractional
shortening 5 (LVIDd2LVIDs)/LVIDd (%); and LV mass 5
1.04 [(IVS 1 PWT 1 LVIDd)3 2(LVIDd)3]213.6 (g) (16).
On two-dimensional echocardiograms, we paid attention to
the presence of any wall motion abnormalities. Three
cardiac cycles were measured and averaged.
Statistical analysis. Differences between the groups of
patients were evaluated by the unpaired t test for continuous
variables and by the chi-square test for categorical variables.
Forward stepwise multiple logistic regression analysis was
used to elucidate the association of LVH with diabetes
transmission and other variables. A p value of ,0.05 was
considered to be statistically significant. Results are pre-
sented as mean value 6SD.
RESULTS
Clinical characteristics and electrocardiographic find-
ings. Of the 834 patients, 121 (15%) had diabetic mothers,
122 (15%) had diabetic fathers and 30 (4%) had both (Table
1). On ECGs, 148 patients fulfilled the LVH criterion of
SV1 1 RV5 or RV6 .35 mm. As a result, the percentage of
patients who had diabetic mothers was significantly higher
in those with the LVH criterion (29%) than in those
Abbreviations and Acronyms
DNA 5 deoxyribonucleic acid
ECG 5 electrocardiogram
HCM 5 hypertrophic cardiomyopathy
IVS 5 interventricular septum
LV 5 left ventricular
LVH 5 left ventricular hypertrophy
LVIDd 5 LV end diastolic internal dimension
LVIDs 5 LV end systolic internal dimension
MELAS 5 mitochondrial encephalomyopathy, lactic
acidosis and stroke-like episodes
NIDDM 5 non–insulin-dependent diabetes mellitus
PWT 5 posterior wall thickness
Table 1. Family History of Diabetes Between Patients With and Those Without LVH
Criterion
Family History of Diabetes Total (n 5 834)
LVH Criterion
(SV1 1 RV5 or RV6 >35 mm)
p Value(1) (n 5 148) (2) (n 5 686)
Mother 151 (18%) 43 (29%) 108 (16%) , 0.001
Father 152 (18%) 26 (18%) 126 (18%) NS
In detail
Mother alone 121 (15%) 35 (24%) 86 (13%) , 0.001
Father alone 122 (15%) 18 (12%) 104 (15%) NS
Mother and father 30 (4%) 8 (5%) 22 (3%) NS
None 561 (67%) 87 (59%) 474 (69%) , 0.025
Data are presented as number (%) of patients. LVH 5 left ventricular hypertrophy.
1373JACC Vol. 33, No. 5, 1999 Momiyama et al.
April 1999:1372–8 Diabetes Transmission and LV Hypertrophy
without it (16%) (p , 0.001), whereas the percentage of
patients having diabetic fathers was similar in those with
LVH (18%) and in those without it (18%) (p 5 NS).
To clarify the association of LVH with maternal trans-
mission of diabetes, 151 patients with diabetic mothers
(group M1) were compared with the other 683 who had
nondiabetic mothers (group M2). As shown in Table 2,
patients in group M1 were younger (56 6 8 vs. 59 6 9
years, p , 0.001) and had earlier onset of diabetes (46 6 9
vs. 49 6 10 years, p , 0.001) than those in group M2. The
percentage of patients who had diabetic siblings was higher
in group M1 (31%) than in group M2 (18%) (p , 0.001).
However, gender, body mass index, diabetes duration and
blood glycemic levels were not different between the two
groups. Hypertension (blood pressures .140/90 mm Hg
and/or on antihypertensive medication) was present in 38%
of group M1 and in 46% of group M2 (p 5 NS), and
blood pressures were not different between the two groups.
Coronary artery disease had been angiographically proven
before this study in 3% of group M1 and in 6% of group
M2 (p 5 NS).
On ECGs, abnormal Q waves were seen in 2% of
group M1 and in 4% of group M2 (p 5 NS) (Table 3).
The voltage combination of SV1 1 RV5 or RV6 was
greater in group M1 than in group M2 (29.3 6 9.1 vs.
27.5 6 8.2 mm, p , 0.02). The LVH criterion of SV1 1
RV5 or RV6 .35 mm was fulfilled in 28% of group M1
compared with 15% of group M2 (p , 0.001). The other
LVH criterion of Romhilt–Estes point score $4 was also
found in 15% of group M1 versus 6% of group M2 (p ,









Age (yr) 56 6 8 59 6 9 , 0.001
Gender (male/female) 93/58 444/239 NS
Body weight (kg) 60 6 12 60 6 11 NS
Body mass index (kg/m2) 22.8 6 3.6 22.9 6 3.5 NS
Onset of diabetes (yr) 46 6 9 49 6 10 , 0.001
Duration of diabetes (yr) 10.0 6 8.0 9.5 6 7.4 NS
Family history of diabetes
Father 30 (20%) 122 (18%) NS
Siblings 47 (31%) 124 (18%) , 0.001
Treatment
Insulin 56 (37%) 250 (37%) NS
Oral hypoglycemic drugs 6 (4%) 40 (6%) NS
Diabetic complications
Retinopathy 51 (34%) 213 (31%) NS
Neuropathy 61 (40%) 266 (39%) NS
Nephropathy 20 (13%) 79 (12%) NS
Fasting plasma glucose (mg/dl) 171 6 45 180 6 52 NS
HbA1c (%) 8.9 6 2.0 9.2 6 1.8 NS
Blood pressures
Systolic (mm Hg) 133 6 18 133 6 21 NS
Diastolic (mm Hg) 74 6 11 75 6 12 NS
Hypertension (.140/90 mm Hg or on
medication)
58 (38%) 313 (46%) NS
Coronary artery disease 4 (3%) 40 (6%) NS
Data are presented as mean value 6SD or number (%) of patients. Hb 5 hemoglobin.
Table 3. Electrocardiographic Findings of Patients Having Diabetic Mothers (M1) and Those









Heart rate (beats/min) 70 6 13 70 6 12 NS
Abnormal Q waves 3 (2%) 24 (4%) NS
SV1 1 RV5 or RV6 (mm) 29.3 6 9.1 27.5 6 8.2 , 0.02
SV1 1 RV5 or RV6 .35 mm 43 (28%) 105 (15%) , 0.001
Romhilt–Estes point score $4 22 (15%) 40 (6%) , 0.001
Data are presented as mean value 6 SD or number (%) of patients.
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0.001). In multivariate analysis, the family history of
diabetes in mothers, hypertension, blood pressure, gender
and body weight were each significantly associated with
the LVH criterion of SV1 1 RV5 or RV6 .35 mm, but the
family history of diabetes in fathers, age, body mass
index, diabetes duration and blood glycemic levels were
not (Table 4). The family history of diabetes in mothers,
hypertension and gender were also significantly associ-
ated with the other LVH criterion of Romhilt–Estes
point score ^4 (Table 5).
Echocardiographic findings. Of the 199 patients who
underwent echocardiography, 42 (21%) had diabetic moth-
ers (group M1), and the other 157 had nondiabetic
mothers (group M2) (Table 6). No difference was found in
the reasons for undergoing echocardiography between the
two groups. Patients were younger in group M1 than in
group M2 (58 6 8 vs. 62 6 8 years, p , 0.002), but
gender, body mass index, diabetes duration and blood
glycemic levels were not different. Hypertension was present
in 52% of group M1 and in 66% of group M2 (p 5 NS),
and blood pressures were not different between the two
groups.
On two-dimensional echocardiograms, LV wall motion
abnormalities were present in 14% of group M1 and in 13%
of group M2 (p 5 NS). On M-mode echocardiograms, LV
internal dimensions and fractional shortening were not
different between the two groups. However, patients in
group M1 had significantly thicker interventricular septum
(9.4 6 1.7 vs. 9.0 6 1.0 mm, p , 0.05) and posterior wall
(9.5 6 1.3 vs. 9.2 6 1.0 mm, p , 0.05) than those in group
M2. Left ventricular mass was also greater in group M1
than in group M2 (158 6 53 vs. 144 6 37 g, p , 0.05).
Left ventricular hypertrophy of wall thickness .12 mm was
found in 17% of group M1 compared with 7% of group
M2 (p 5 NS).
DISCUSSION
On ECGs, the voltage criterion of SV1 1 RV5 or RV6
.35 mm is widely used and highly specific for detecting
LVH (14,17). Using this ECG LVH criterion, we investi-
gated the association of diabetes transmission with LVH in
NIDDM. In patients with NIDDM, LVH was significantly
more prevalent in those with diabetic mothers than in those
with nondiabetic mothers. In multivariate analysis, maternal
transmission of diabetes was associated with LVH indepen-
dent of hypertension, obesity and the duration and control
of diabetes. The fact that patients with diabetic mothers
were younger than those with nondiabetic mothers was
noteworthy, because LVH increases with age. Despite the
younger age, the higher prevalence of LVH in patients with
diabetic mothers suggests the further association of mater-
nal transmission of diabetes with LVH. Moreover, patients
with diabetic mothers had earlier onset of diabetes and
higher prevalence of diabetes in siblings than those with
nondiabetic mothers, suggesting a strong genetic basis in
maternally transmitted NIDDM. These results suggest that
some genetic factors of diabetes could be contributing to the
development of LVH in maternally transmitted NIDDM.
However, the increased prevalence of LVH was not found
in paternally transmitted NIDDM.
Because falsely high QRS voltages are often seen in
young people (18) and extracardiac factors, such as obesity,
attenuate QRS voltages (19), patients with diabetic mothers
may have had more false positive LVH on ECGs. Grub-
schmidt and Sokolow (20) reported that LVH voltage
criteria are reliable in adults over the age of 25 years,
Table 5. Multiple Logistic Regression Analysis in 834 Diabetic Patients
Variables Beta SE Chi-square p Value OR (95% CI)
Hypertension 1.299 0.293 19.7 , 0.001 3.67 (2.07–6.52)
Family history of diabetes in mothers 1.182 0.294 16.1 , 0.001 3.26 (1.83–5.81)
Gender (female 5 0, male 5 1) 1.068 0.338 10.0 0.002 2.91 (1.50–5.64)
The dependent variable was the left ventricular hypertrophy criterion of Romhilt–Estes point score $4. The analysis included age, gender, body weight, body mass index, diabetes
duration, family histories of diabetes in mothers and fathers, fasting plasma glucose, hemoglobin A1c, hypertension and blood pressure. CI 5 confidence interval; OR 5 odds
ratio.
Table 4. Multiple Logistic Regression Analysis in 834 Diabetic Patients
Variables Beta SE Chi-Square p Value OR (95% CI)
Gender (female 5 0, male 5 1) 1.135 0.247 21.2 , 0.001 3.11 (1.91–5.05)
Family history of diabetes in mothers 1.027 0.228 20.3 , 0.001 2.79 (1.79–4.36)
Blood pressure (mm Hg) 0.023 0.006 13.1 , 0.001 1.02 (1.01–1.03)
Body weight (kg) 20.035 0.010 11.3 , 0.001 0.97 (0.95–0.99)
Hypertension 0.891 0.273 10.6 0.001 2.44 (1.43–4.16)
The dependent variable was the left ventricular hypertrophy criterion of SV1 1 RV5 or RV6 .35 mm. The analysis included age, gender, body weight, body mass index, diabetes
duration, family histories of diabetes in mothers and fathers, fasting plasma glucose, hemoglobin A1c, hypertension and blood pressure. CI 5 confidence interval; OR 5 odds
ratio.
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although 13% of people between the ages of 20 and 25 years
show false positive. To reduce false positive, we excluded
patients younger than 40 years. The higher prevalence of
LVH in patients with diabetic mothers was also shown by
Romhilt–Estes point score, which incorporates nonvoltage
criteria. In multivariate analysis, the association of maternal
transmission of diabetes with LVH was independent of age
and obesity. Hence, the possibility of more false positive
LVH in patients with diabetic mothers is slim. Although
echocardiography was not performed in all our study sub-
jects, it showed greater LV wall thickness and mass in
patients with diabetic mothers than in those with nondia-
betic mothers. It suggests that the higher prevalence of
LVH on ECGs in patients with diabetic mothers reflects
more hypertrophied LV associated with more thickened LV
wall.
Left ventricular hypertrophy in diabetes. It is well known
that LVH is often seen in diabetic patients (1–4). Autopsy
studies reported marked LVH in diabetic patients who died
of heart failure in the absence of coronary artery disease
(21–23). Although LVH in diabetes could be attributed to
coexisting hypertension and obesity (5–8), recent studies
documented that diabetes is associated with LVH indepen-
dent of hypertension and obesity (9,10). Moreover, Gross-
man et al. (24) showed that in patients with hypertension,
diabetes accelerates the development of LVH. Clinical and
experimental studies demonstrated interstitial myocardial
accumulation of collagen and glycoprotein (25–27) and
metabolic alterations of myocardium in diabetes (27–29).
However, the pathogenesis of LVH in diabetes has not been
fully clarified.
Left ventricular hypertrophy and mitochondrial deoxyri-
bonucleic acid (DNA) mutations. Hypertrophic cardio-
myopathy (HCM) characteristic of marked LVH is one of
the most common forms of genetic heart disease. Watkins
et al. (30,31) showed that about 50% of familial HCM is
caused by nuclear DNA mutations in cardiac beta myosin
heavy-chain or troponin T genes. Because these nuclear
DNA mutations are transmitted as an autosomal dominant
trait, they cannot account for LVH in maternally transmit-
ted diabetes.
Mitochondrial DNA mutations have been reported in
some patients with HCM (32,33). Obayashi et al. (34)
detected mitochondrial DNA mutations in seven patients
with non–autosomal dominant HCM and suggested that
these mutations are one of the causes of non–autosomal
dominant HCM. The theory is based on the fact that
mitochondrial DNA genes are exclusively maternally trans-
mitted. Recently, in patients with maternally transmitted
HCM, mitochondrial DNA mutations were reported as the
cause of their HCM (35–38). On the other hand, the
syndrome mitochondrial encephalomyopathy, lactic acidosis
and stroke-like episodes (MELAS) are known to be caused
by a mitochondrial DNA mutation at position 3243 (39). In
MELAS, LVH is considered to be the clinical feature of
cardiac involvement (40–43). Ito et al. (43) reviewed 21
patients with MELAS and found LVH in eight patients.
Marked LVH as seen in HCM was reported in some
patients with MELAS (44,45). Ultrastructure of their
myocardium showed markedly increased mitochondria.
Hence, it is reasonable to think that maternally transmitted
LVH may be related to mitochondrial DNA mutations.
Maternally transmitted diabetes. Recently, it has been
suggested that maternally transmitted diabetes is associated
with mitochondrial DNA mutations (46–53). Katagiri et al.
(48) reported that 1.3% of maternally transmitted diabetes is
caused by a mitochondrial DNA mutation at position 3243
and that this mutation manifests a wide range of diabetic
phenotypes from NIDDM to IDDM. Kishimoto et al. (49)
detected this mutation in 5.1% of patients with maternally
transmitted NIDDM. Other mutations at position 3256,
3260, 3264, 3271 or 8344 were also documented to cause
diabetes (35,50–53). Because maternally transmitted diabe-
tes could be associated with mitochondrial DNA mutations
and because mitochondrial DNA mutations can be a cause
of LVH, it is reasonable to think that latent mitochondrial
DNA mutations could contribute to LVH in maternally
transmitted NIDDM. Moreover, Poulton et al. (54) re-
cently documented that 17% of patients with NIDDM have
Table 6. Echocardiographic Findings of Patients With Diabetic Mothers (M1) and Those






(n 5 157) p Value
LVIDd (mm) 43.4 6 4.3 43.0 6 4.2 NS
Fractional shortening (%) 41 6 11 42 6 10 NS
Wall motion abnormality 6 (14%) 20 (13%) NS
Interventricular septum (mm) 9.4 6 1.7 9.0 6 1.0 , 0.05
Posterior wall thickness (mm) 9.5 6 1.3 9.2 6 1.0 , 0.05
Wall thickness .12 mm 7 (17%) 11 (7%) NS
LV mass (g) 158 6 53 144 6 37 , 0.05
Data are presented as mean value 6 SD or number (%) of patients. LV 5 left ventricular; LVIDd 5 LV end-diastolic internal
dimension.
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a mitochondrial DNA variant at position 16189. This
variant was shown to be associated with insulin resistance,
and it was suggested to be a premutation for pathogenic
mutations. In addition to the mutations, such mitochondrial
DNA variants may contribute to the development of LVH
as well as NIDDM.
The intrauterine environment of diabetes is also recog-
nized to play a role in maternally transmitted NIDDM.
Pettitt et al. (55) reported the higher prevalence of NIDDM
in offspring of diabetic mothers than in those of mothers
who became diabetic after pregnancy. They also showed
that diabetic intrauterine environment has a long-term
effect on glucose tolerance in offspring, so-called “program-
ming” (56). It can be speculated that the fetal programming
of the diabetic intrauterine environment may change sus-
ceptibility to LVH and that this effect may be additional to
those of genetic factors. However, there is no report to
support this speculation, and the onset of NIDDM is
usually after childbearing age (57).
Conclusions. Maternal transmission of diabetes was asso-
ciated with LVH in patients with NIDDM. This suggests
that some genetic factors of diabetes, such as mitochondrial
DNA abnormalities, may contribute to the development of
LVH in maternally transmitted NIDDM.
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